HOPKINTON, Mass., April 9 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced an agreement with Pfizer Inc. (NYSE: PFE) under the terms of which Caliper’s Discovery Alliances & Services division will conduct certain in vivo profiling experiments for Pfizer. These will enable Pfizer to explore new indications for some compounds in its research and development pipeline.
This is an important agreement for Caliper and was anticipated. Under the one-year contract, Caliper will utilize its in vivo compound profiling platform to study the effects of acute or chronic drug dosing in mice to try and uncover new uses for compounds already in development. Identifying the potential for drug candidates to treat different conditions is a common strategy in pharmaceutical R&D.
“On average, a drug has six and a half to seven years of patent life remaining after being launched,” said Kevin Hrusovsky, president and CEO of Caliper Life Sciences. “Our portfolio of advanced in vitro and in vivo capabilities is being leveraged by pharmaceutical companies to explore the potential for drugs to treat indications beyond their original design.”
About Caliper Life Sciences Caliper Life Sciences is a leading provider of drug discovery and life sciences research solutions for the pharmaceutical and biotechnology industries. With its acquisitions of NovaScreen Biosciences and Xenogen Corporation, Caliper has positioned itself to transform drug discovery and development through a keen focus on clinically relevant experimentation. Caliper’s products and services, assembled from a leading portfolio of microfluidics, liquid handling, and imaging technologies, span in vitro and in vivo experimentation and address key issues on the critical path of drug discovery and development. More information about Caliper can be found at http://www.caliperLS.com. Caliper is a registered trademark of Caliper Life Sciences, Inc.
SOURCE Caliper Life Sciences, Inc.
